LY2090314 is a potentGSK-3inhibitor forGSK-3α/βwith IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of ki In vitro
LY2090314 selectively inhibits the activity of GSK-3 by interrupting ATP binding. LY2090314 is able to stabilize β-catenin. LY2090314 shows limited efficacy as monotherapy. LY3090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer cell lines in vitro.
In vivo
LY2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts. Cell Data